文献速递糖尿病

血浆甲基乙二醛水平与严重肢体缺血患者截肢和死亡相关

Plasma Methylglyoxal Levels Are Associated With Amputations and Mortality in Severe Limb Ischemia Patients With and Without Diabetes.
PubMed 文献 · Diabetes Care · 2020-11-03

本研究在160例无选项严重肢体缺血患者中检测基线血浆甲基乙二醛(MGO)等指标,随访5年记录主要不良结局。发现较高血浆MGO水平与更多不良结局和截肢相关,MGO衍生的AGE Nε-羧乙基赖氨酸亦与不良结局和截肢相关,提示MGO可能为SLI预后标志。

要点

  • 血浆MGO每升高1个标准差,不良结局相对风险1.44,截肢风险1.55。
  • MGO衍生的AGE Nε-羧乙基赖氨酸与不良结局和截肢相关。
  • d-乳酸与不良结局无关,MGO或为SLI干预靶点。

核心结论

  • 血浆MGO水平与严重肢体缺血患者不良结局相关,未来需研究靶向MGO治疗是否改善结局。

研究设计与样本

  • 在160例无选项严重肢体缺血患者中,用超高效液相色谱-串联质谱法检测基线血浆MGO、游离AGEs和d-乳酸,随访5年记录主要不良结局。

主要发现

  • 血浆MGO每升高1个标准差,不良结局相对风险1.44(95%CI 1.11-1.86),截肢相对风险1.55(95%CI 1.13-2.21),死亡相对风险1.28(95%CI 0.93-1.77)。
  • MGO衍生的AGE Nε-羧乙基赖氨酸每升高1个标准差,不良结局相对风险1.46(95%CI 1.00-2.15),截肢相对风险1.71(95%CI 1.04-2.79)。
  • d-乳酸与不良结局无关;较高血浆MGO水平与更多炎症、白细胞增多和祖细胞减少相关。

临床怎么用

  • 血浆MGO水平或可用于严重肢体缺血患者截肢和死亡风险分层。

局限性

  • 研究为观察性设计,不能确定MGO与不良结局的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Diabetes is a risk factor for severe limb ischemia (SLI), a condition associated with high mortality, morbidity, and limb loss. The reactive glucose-derived dicarbonyl methylglyoxal (MGO) is a major precursor for advanced glycation end products (AGEs) and a potential driver of cardiovascular disease. We investigated whether plasma MGO levels are associated with poor outcomes in SLI. RESEARCH DESIGN AND METHODS: We measured plasma levels of MGO, free AGEs, and d-lactate, the detoxification end product of MGO, with ultraperformance liquid chromatography-tandem mass spectrometry at baseline in 160 patients (64.8 ± 13.3 years, 67.5% male, 37.5% with diabetes) with no-option SLI and recorded major adverse outcomes (n = 86, comprising n = 53 deaths and n = 49 amputations [first event counted]) over the 5-year follow-up. Data were analyzed with linear or Cox regression, after Ln-transformation of the independent variables, adjusted for sex, age, trial arm, diabetes, estimated glomerular filtration rate, systolic blood pressure, cholesterol levels, and BMI. Associations are reported per 1 SD plasma marker. RESULTS: Higher plasma MGO levels were associated with more adverse outcomes (relative risk 1.44; 95% CI 1.11-1.86) and amputations separately (1.55; 1.13-2.21). We observed a similar but weaker trend for mortality (1.28; 0.93-1.77). The MGO-derived AGE Nε-(carboxyethyl)lysine was also associated with more adverse outcomes (1.46; 1.00-2.15) and amputations (1.71; 1.04-2.79). d-Lactate was not associated with adverse incident outcomes. Higher plasma MGO levels were also associated with more inflammation and white blood cells and fewer progenitor cells. CONCLUSIONS: Plasma MGO levels are associated with adverse outcomes in SLI. Future studies should investigate whether MGO-targeting therapies improve outcomes in SLI.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Hanssen NMJ, Teraa M, Scheijen JLJM, et al. Plasma Methylglyoxal Levels Are Associated With Amputations and Mortality in Severe Limb Ischemia Patients With and Without Diabetes. Diabetes Care. 2020. PMID: 33144352. doi:10.2337/dc20-0581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。